IntelGenx begins patient dosing in VersaFilm Phase 2a AD study
IntelGenx (TSXV:IGX; OTCQX:IGXT) began patient dosing in the Phase 2a study of Montelukast VersaFilm in patients with mild-to-moderate Alzheimer’s disease (AD).
The True North Clinical Research site in Kentville, Nova Scotia is the first of eight research sites in Canada to enrol a patient and begin dosing.
The randomized, double blind, placebo controlled Phase 2a proof-of-concept study will enroll approximately 70 subjects with mild-to-moderate AD. The study will evaluate the safety, feasibility, tolerability, and efficacy of montelukast buccal film following daily dosing for 26 weeks. Seven-of-eight research sites are actively recruiting patients.